Neoleukin Therapeutics
PUBLIC
STATUS
1-10
EMPLOYEES
NLTX
STOCK SYMBOL
1
INVESTMENTS
$10.56
SHARE PRICE
(As of Friday Closing)
Description
Neoleukin Therapeutics Inc operates as a biopharmaceutical company. It generates immunotherapies using de novo protein design technology. The firm uses computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins to treat serious diseases, including cancer, inflammatory, and autoimmune disorders. Its product line comprises of NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding.
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Discovery Tools (Healthcare)
Stock Exchange
NAS
Primary Office
- 401 Terry Avenue North
- Seattle, WA 98109
- United States
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Neoleukin Therapeutics’s full profile, request a free trial.
Neoleukin Therapeutics Stock Performance
| 52 wk Range | Market Cap | Prev. Close | EPS | Average Volume | Shares |
|---|---|---|---|---|---|
| $2.18 - $13.43 | $513M | $10.46 | -$2.71 | 536K | 48.6M |
Neoleukin Therapeutics Financials Summary
|
In Thousands,
USD |
TTM
30-Sep-2019
|
FY 2018
31-Dec-2018
|
FY 2017
31-Dec-2017
|
FY 2016
31-Dec-2016
|
|---|---|---|---|---|
| Enterprise Value | 7,918 | (35,880) | 156,290 | 240,806 |
| Revenue | 0 | 25,000 | 0 | 0 |
| EBITDA | (67,972) | (33,144) | (51,177) | (37,620) |
| Net Income | (66,228) | (31,585) | (50,183) | (37,002) |
| Total Assets | 69,791 | 77,618 | 110,329 | 154,380 |
| Total Debt | 616 | 6 | 33 | 47 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Neoleukin Therapeutics Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore Neoleukin Therapeutics‘s full profile, request access.
Request full access to PitchBookNeoleukin Therapeutics Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 0000000 0000000000 | 09-Aug-2019 | 000000000000000000 | Drug Discovery | 00000000 00000000 00 |
Neoleukin Therapeutics Executive Team (6)
1 Former Executive
You’re viewing 5 of 6 executives. Get the full list »Neoleukin Therapeutics Board Members (6)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Cantey Boyd | Self | Board Member | 000 0000 | |
| Jonathan Drachman MD | Neoleukin Therapeutics | Chief Executive Officer & Chairman | 000 0000 | |
| Lewis Williams Ph.D | Neoleukin Therapeutics | Board Member | 000 0000 | |
| Sarah Noonberg MD | Self | Board Member | 000 0000 | |
| Sean Nolan | Self | Board Member | 000 0000 |